Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
New data from a National Institutes of Health-funded study shows that midlife, the immune cell landscape of the hippocampus, undergoes substantial remodeling. It points to a potential mechanism by which aging may contribute to the chronic neuroinflammation commonly seen in neurodegenerative disease. Details are published in a new Science paper titled “ Epigenetic and 3D genome reprogramming during the aging of human hippocampus .”
Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides
Samsung Biologics made an all-cash public tender offer of approximately $1.8 billion to acquire Switzerland-based PolyPeptide Group, a CDMO specializing in peptide-based active pharmaceutical ingredients (APIs).
‘Not Your Average Chickpea’: NuCicer Unveils Higher-Protein Version of Beloved Bean
The protein craze has birthed its newest tech-led innovation: ultra-high-protein chickpeas.Californian startup NuCicer, which uses artificial-intelligence-assisted (AI) technologies to design crops with enhanced functionalities, has launched a new range of chickpeas that contain 50% more protein and 25% less fat than conventional varieties of the bean.
Bezos Centre for Sustainable Protein Kicks Off Equity-Free Future Food Accelerator
Bezos Earth Fund is extending its future food focus by building on its ongoing partnership with Imperial College London to help startups navigate the food tech ”valley of death”.
Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies
Chris Moxham, PhD, has been a “drug hunter” for three decades, building data-driven platforms as vice president of quantitative biology at Eli Lilly, and CSO of Folcrum Therapeutics, in recent years.
USDA Asks Partners to Develop AI Solutions to Accelerate Crop Innovation
July 2026, Washington: The U.S. Department of Agriculture (USDA) is taking steps to speed up progress in plant science b…
🎥 Can editing the ‘dark genome’ make crops more heat tolerant?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Plantik Biosciences.] Can editing the so-called “da…
Neurimmune turns future royalties into $425m pipeline cash
Why it matters: The deal allows Neurimmune to raise substantial non-dilutive funding without issuing shares. Since the responsibility for cliramitug’s costly late-stage development already sits with AstraZeneca, this money can directly be invested in the development of earlier-stage assets.
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
🎥 Can editing the ‘dark genome’ make crops more heat tolerant?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Plantik Biosciences.] Can editing the so-called “da…